var data={"title":"Society guideline links: Hemophilia, von Willebrand disease, and other coagulation disorders","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Society guideline links: Hemophilia, von Willebrand disease, and other coagulation disorders</div><p class=\"disclosureLink\"></p><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H3393918008\"><span class=\"h1\">Introduction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.</p><p>The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.</p><p>Links to related guidelines are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-immune-thrombocytopenia-itp-and-other-platelet-disorders\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Immune thrombocytopenia (ITP) and other platelet disorders&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1985356292\"><span class=\"h1\">International</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/jth.12964/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKTMITkuZDQw5GQyHgq2ZRGcwW7I6HEXCDHLA60AI+IB0g==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">International Society on Thrombosis and Haemostasis (ISTH): Recommendations and guidelines on platelet-dependent von Willebrand factor activity &ndash; Nomenclature and methodology</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/jth.12672/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKTMITkuZDQw5GQyHgq2ZRGcOw/uM/9upcOxMD50qgk3sQ==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">ISTH: Recommendations and guidelines on definitions in hemophilia</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.rarecoagulationdisorders.org/&amp;token=3P39bFY6QkFxXEfCK67hxrjuQcgPSOuY0YwFWXBEMPP5HqXZqEUtHgHoy+58KLmSrwC1JCwUsNIWoeWxLU0oqw==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">Rare Bleeding Disorders Database (RBDD), Indiana Hemophilia and Thrombosis Center (IHTC), and National Hemophilia Foundation (NHF): Rare coagulation disorders resource room</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/jth.12155/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKTMITkuZDQw5GQyHgq2ZRGcBRXDh5PHhhrnMCyOj0pOnQ==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">ISTH: Guidance for diagnosis and treatment of disseminated intravascular coagulation from harmonization of the recommendations from three guidelines</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www1.wfh.org/publications/files/pdf-1512.pdf&amp;token=jfTQokD1X78t1hOGjoAhg45vEAH+nVHtLnHZJ70BXc7iI1vfxKckAx3TS3bQ9zLCka+BC7/1EnYlXPvAxo24Sg==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">World Federation of Hemophilia (WFH): Guidelines for the management of hemophilia, selected updates</a> (2013)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"http://www1.wfh.org/publications/files/pdf-1472.pdf&amp;token=jfTQokD1X78t1hOGjoAhg45vEAH+nVHtLnHZJ70BXc6oAsNCtaqZi7vMRxnvZ94qCaYNzS7FRjHCL5n8FkJhMQ==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">WFH: Guidelines for the management of hemophilia, 2nd edition</a> (2012)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.aabb.org/pbm/Documents/guidelines-for-plasma-transfusion.pdf&amp;token=OnbhFYG+9t0Q/hlZKI68bK/WY1MSSmEUc/Jt9MvZ1GLwFVK2z2xhFJV4OuigrAoTD/C5xrMVJ9+mkWiLhDgVlEElW9q51GEmKr0xPLaSEu4=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">AABB: Evidence-based practice guidelines for plasma transfusion</a> (2010)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.haematologica.org/content/94/4/566.long&amp;token=y6FUHJH3MpZ/fPODTo9FRxD73bkZDoVPcem+x/w21794w0Pze/NcvbZM5zaXh+Kvh51674+/tmYGuus0u+Aa/A==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">International recommendations on the diagnosis and treatment of patients with acquired hemophilia A</a> (2009)</p><p/><p class=\"headingAnchor\" id=\"H947502612\"><span class=\"h1\">Canada</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.nacblood.ca/resources/guidelines/downloads/Criteria_Alprolix_Eloctate.pdf&amp;token=iiUGmits8XhYFVUWf9brgGfXasvtlod/igLji4EeEAbt154GDpNacRGvS4ngzyEwtEQXhxXN0rFA8umwMWiHhtI6QWjjgbf2MprNPuVMf6qXQr7EEclYPdtj6njNdouu&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">National Advisory Committee on Blood and Blood Products (NAC): Criteria for starting patients on long-acting factor products and monitoring of utilization</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/hae.13008/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKTSIcSSqHz1bieqe6BE8QgNRyfHrkZKSJUOmuxAAxJMDQ==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">National Hemophilia Foundation (NHF)-McMaster University: Guideline on care models for haemophilia management</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.nacblood.ca/resources/guidelines/SD+Plasma/SD-plasma.pdf&amp;token=W+V6hvKS0rORATNdvWG3U7D/roT5VuFzLPPVEYe2NfFzrG1StUGoWjPTo1UM/X5MocQ9AbjEzoSac1ZKaDXlHQKENXaFEcsqXykGTqoNWc4=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NAC: Framework for appropriate use and distribution of solvent detergent treated plasma in Canada</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.nacblood.ca/resources/guidelines/fibrinogen.html&amp;token=VSJ0p6gFmLtocV34LKbCbXHOgGVSyngmsKDxw2mjs9bvMCzJun4DoMrMYr+t7PpTQs2eFyyKkE+ES+z84YIQYg==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NAC: Recommendations for use of fibrinogen concentrate in acquired hypofibrinogenemia</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.ca/files/VWD+Guidelines+EN+by+e-mail.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M2HCsbCnndAZDVZrWPSoFdgk1Ihebqm7AiRq3Eg2NARL0c0JMDRVBkzp690qiu9/Et8GCAaWMXrdKBVRq5eKGUQ=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">Canadian Hemophilia Society (CHS): Guidelines for the diagnosis of von Willebrand disease (VWD)</a> (2012)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3148.2012.01164.x/pdf&amp;token=NXudv8qPw31y93mxgkUYj4u8LrTcoQH2XKXK6MGt+SjnTPN0K4b8WHbToJwidu+rK71hfM1d4YEHvsugEPpwJJZedKLzQr+INRPb+YCea+U=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NAC: The evidence for the use of recombinant factor VIIa in massive bleeding &ndash; Revision of the transfusion policy framework</a> (2012)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.sciencedirect.com/science/article/pii/S0887796307000028&amp;token=kfDaku7Z+KfeT5fgXqtcyMn0Pz2Hqdpq6bC8AyA/9SYDjnqbtF0zXz3UYFTG93rXSuazKTyd2JvqPXRerww0ukolyC7tTA+NduGJprimN3c=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NAC and Canadian Blood Services (CBS): Guidelines on the use of intravenous immune globulin for hematologic conditions</a> (2007)</p><p/><p class=\"headingAnchor\" id=\"H3915409515\"><span class=\"h1\">United States</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/252+ER+Management.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJv1RDkvpiGaE8kbWLS05QMXGUxBFGJQdBJAonpao4iKnY=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">National Hemophilia Foundation (NHF): Guidelines for emergency department management of individuals with hemophilia and other bleeding disorders</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/251+Delivery+Guidelines.pdf&amp;token=Qb5qJBGb5o9n4ovnfsO/hjI5GZtW0RV2jaP5Y2MwKjHmOQ1YTRpQToCU1XY/zySREvdA5EqzHlO+h0PpMYcLOgs0DluZvcBm5AljtxhNBaNxh6QL/Ce485yJAedHAf1H&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A or B</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/250+Treatment+text++2017.pdf&amp;token=Swo12q5mE0eWuGI7/SNrX/WR0R5RJv5dNNTr57apOp7c2J62pw2sNFlytnedKxWWDaDXjoUVxAgjXYbxVfmfqgXtDrriyveQAZ52yoQ2Xi4RPtDmIfUMH0q3PZFlaxDZ&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders</a> (revised 2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/hae.13008/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKTSIcSSqHz1bieqe6BE8QgNRyfHrkZKSJUOmuxAAxJMDQ==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF-McMaster University: Guideline on care models for haemophilia management</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/241Prophylaxis.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJvyw1AF23SIXwfPZplL0VxBXE9KiNhGPmtue3Vte1itLc=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding)</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/243SIPPET.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJvrZxtKIoRC+QIF5KDczon0t7yb8H86xAAxyB9EaRFufU=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendation on SIPPET (Survey of Inhibitors in Plasma-Product-Exposed Toddlers) &ndash; Results and recommendations for previously untreated patients with hemophilia</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/247.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJv2HO79KoWPDb1p9tMFdWOAZIEtJHdI5qVaC6O2dRFHVU=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations on treatment of hepatitis C in individuals with hemophilia and other bleeding disorders</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/242.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJvaOGABY8QIv1PI6O5m86suNsBAH9ea0YaG/ads4EyiWw=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations regarding doses of clotting factor concentrate in the home</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/245.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJvr0HCZdTMJYlY+J8EBdrHvD0Dfd9BUY7wt6nBFjOSPpA=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations regarding girls and women with inherited bleeding disorders</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/244.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJvaE14IEaAxE2Rpr866bdCtMOcMzsCNJIq2VZFi6t/ugE=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations regarding the treatment of von Willebrand disease</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.acog.org/-/media/Committee-Opinions/Committee-on-Adolescent-Health-Care/co580.pdf?dmc=1&ts=20170327T1849382881&amp;token=XioKIMYL9AeCrGMTKHzDepC1rIEaokNwpeVXj8EFY9mm2ApUNyDzW0nurk2YJcO6OpsNk5+RipK7miyVTpqLa/gxPdQ1qos/LKsJt6NnhIfqUI1bH84Naelc7OrpA+EwGG2wMf2TmYL4LvaVrRXoST87P9a4wAjYgyhcUh+pmUA=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">American College of Obstetricians and Gynecologists (ACOG): Committee opinion on von Willebrand disease in women</a> (2013, reaffirmed 2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/233HomeAdministration.pdf&amp;token=uxUobvQSTrCWWBtKUMkHy60CQqmFFY8MIgZT1HsxB2zpuwI6MxXw1JTzmLuwmGzyyeZbEdR0SVEY1yqkOzYZI2xHK8WR8LCf08l9jLGjGxavALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendation on administration of inhibitor bypassing agents in the home for patients with hemophilia and inhibitors</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/236.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJv5xRkfUynwt1aSuwNKZnASf6Db0AKGhNe2cgi4JUziRs=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations on standardized testing and surveillance for inhibitors in patients with hemophilia A and B</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/232VWDresolution.pdf&amp;token=dPU+kwiAKnJFCTzFjObwSilcTN2JhnpzChwzxkH/9fCeokVKFSEEJPETnWMNxo5rm4ls22j+dxms6/QB7WHAzQ6HRViW8aWX7bnqE3T5AQM=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations on the care and treatment of individuals with von Willebrand disease</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-Regarding-Physical-Therapy-Guidelines-in-Patients-with-Bleeding-Disorders&amp;token=lfdYslBxLaaBM57KxsuXixwGz2GSZ/P6K0wgePmDHIPEHy4ISw2DKvQtALH2f6gjqT53/rx4ixkZ4vXmOjaza8q051gxNiybobSww0Y7dCRTIjmFnLrhjKEJvKiS8FQE67Phq0IsfyeaJSQ/h7hWlWyveg9NjKGlTvd+fLizEbqgJmZQn/is4cGOgtM3EbhWjyBurmpKMJPWNu+fpLY73u182z2bJyFkd3seZ7M6/a0=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations regarding physical therapy guidelines in patients with bleeding disorders</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac-227.pdf&amp;token=AW/3NElBYGZ0g8q2csEvv9PvZGrom5dj8aNVCNCzNVbO+ZoFIMT+6sux96qWghFvzo/fxTW8bq6LgJLJ8OSoOwmq8C/VpUDMorVWSu/xRw0=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendation regarding home factor supply for emergency preparedness for patients with hemophilia and other bleeding disorders</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac-226.pdf&amp;token=UcFUvkG4z+3opNcx7GsYgeFE9UqFose+NrBcsqHm+dLZXKaC48+CZLOHwsWXWmrfySxYkj5DmXK6XI5L+HELq6myHGSHgWN4WbJ9/eVLcQc=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendation regarding the use of recombinant clotting factor products with respect to pathogen transmission</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac-228.pdf&amp;token=Gy/RezUYxaxtismsXooeuBo6rtcKWYznNELtT0rq8KsLxDI3dm28xX/oXBhV8ySbIo61sS9EZ6SmSudZWC4wQEU31Kfn0Ym+weqnx56FIVI=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC statement regarding use of various clotting factor assays to monitor factor replacement therapy</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.rarecoagulationdisorders.org/&amp;token=3P39bFY6QkFxXEfCK67hxrjuQcgPSOuY0YwFWXBEMPP5HqXZqEUtHgHoy+58KLmSrwC1JCwUsNIWoeWxLU0oqw==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">Rare Bleeding Disorders Database (RBDD), Indiana Hemophilia and Thrombosis Center (IHTC), and NHF: Rare coagulation disorders resource room</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.choosingwisely.org/clinician-lists/american-society-clinical-pathology-bleeding-time-test/&amp;token=xnqOxsNlBQyGnfhfWqQCLBPIrjqaqK7K8Y0D8vq7y6RHlyzTWrE13sq44mUG+2l0lRWkNTW+9EpJqi8JRwrI/X+CYp0ysRNk6+mhaBT+FezNYIacJuQ2HSPxEhz2W0QW&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">Choosing Wisely: Don't use bleeding time test to guide patient care</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac221.pdf&amp;token=GbdkfyuHkuqUUhoJtONxfaaXBQ/MLvjp49KpxMyrYRDs8CPwkXG1lcfg/3zfFpspCWK7GHZCPGIVyyVpnEyjU3Y18ZMrVRI6+ubVZchzFo8=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations on administration of vaccines to individuals with bleeding disorders</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac223.pdf&amp;token=nBlKmN299NCnLBD3oRHsFltE3xLEBASz7L5VXhWAi2c0yyqgaEg35FTk3cS4ol0C4dU6AVkylzeGPAKgXnYTM3sI+ct/GShVZcSav9T56JM=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations on liver biopsy in individuals with hemophilia</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac220.pdf&amp;token=3v9Hg8vQIFljo+oSYGWRFaaXBQ/MLvjp49KpxMyrYRDs8CPwkXG1lcfg/3zfFpspCWK7GHZCPGIVyyVpnEyjU9T8EZVhvGfYMBAvPOZEGfU=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations regarding prophylaxis with bypassing agents in patients with hemophilia and high titer inhibitors</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac216.pdf&amp;token=Xa1GQINUy3uRfh7JgurE62bzRlkT/aFHDclXBhB6bpn07uJuiDue85t03jb6/xH4A80PLVMUgqITYSU5mh+C5s1pCj1pPnKDUxkDPIZ+Vuc=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC statement regarding inhibitor risk of factor VIII concentrates</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Reference.aspx&amp;token=4Caklgg7Vh7UQhofgcIYpnWoKi6Z2Ingr67hAuJsf8gzbGZQ0AfyaAzx7Y1bEJ50SKZlDnjo4h7wEDnxOqQ8DEEJX5oc7yXDAyJmWXCe5GY=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">American Society of Hematology (ASH): Clinical practice guideline on the evaluation and management of von Willebrand disease (VWD) &ndash; Quick reference</a> (2007, revised 2012)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac211.pdf&amp;token=tweGdS/kVIEIO3UK2OUVX6aXBQ/MLvjp49KpxMyrYRDs8CPwkXG1lcfg/3zfFpspzQNJpLKgayGx9n9rJrYOBxicVq/ijuAazSf0bkFgEFI=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations regarding inhibitor risk and recombinant factor VIII concentrates</a> (2012)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/174.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJvVJODEXy30wHXdv9KrPvh3VLx8kC67nsIBalkb/rg13w=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations regarding rare coagulation factor disorders</a> (2011)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac188.pdf&amp;token=/EFnD8OfiJ5b1kUYVhu0rltE3xLEBASz7L5VXhWAi2c0yyqgaEg35FTk3cS4ol0CiJCkQV9T+e3tyy0EIJS5RdXxDG+ugDX/wSMFOanA/OM=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations regarding standards of service for pharmacy provides of clotting factor concentrates for home use to patients with bleeding disorders</a> (2008)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.nhlbi.nih.gov/files/docs/guidelines/vwd.pdf&amp;token=xtgKad1PPVXLE455JONyobd4rGnS0ODlvkVQfizxxCJKjVpBRT5w71ObbjidwYr10HQWhJUFjiscEEG6TCsQ2Q==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">National Heart, Lung, and Blood Institution (NHLBI): Full report on the diagnosis, evaluation, and management of von Willebrand disease</a> (2007)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/167.pdf&amp;token=SzDUOnM2qUS6i9rhTg33M1Kv0Ux60Vst3ebsjlsth2wKKZxlA8e6bTuHNPmT3SJvOHzgs0NHIwDYX0AK06ywaLms6U55vSmKGXbiopttAH8=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendation regarding the use of bypassing agents in patients with hemophilia A and B or inhibitors</a> (2006)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac159.pdf&amp;token=pzH97MGbBdRzHd8sf5yK4WbzRlkT/aFHDclXBhB6bpn07uJuiDue85t03jb6/xH4UXAIrzekSsgnZKmqTWPODkwMlzK3/xleFFC8VZzfG1s=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendation regarding factor concentrate prescriptions and formulary development and restrictions</a> (2005)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac162.pdf&amp;token=Xa1GQINUy3uRfh7JgurE62bzRlkT/aFHDclXBhB6bpn07uJuiDue85t03jb6/xH4Dlzrp/tG5gL4Gj1D/HSWJJxlQQlRGz31Xw1jpSRPclo=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: MASAC recommendations on use of COX-2 inhibitors in persons with bleeding disorders</a> (2005)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac147.pdf&amp;token=s3n3+qxNLoYF2Sa8qkrM5FtZUg9IbMSxTC6EgiGobpvFyPuYjkKOVFWDb8DZyrsW/4/VjOdBAWtjPVwHWZoGWv42hizvy1VMlTQNTbaN3rI=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: Transition guidelines for people with bleeding disorders</a> (2003)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.hemophilia.org/sites/default/files/document/files/masac132.pdf&amp;token=K+kmhuU5tbddD031/6cH8gMFPbycvv1rciZ5sOrsAw3IxWNKqKCZYjhf7y+tDisKISJ++POFxC5Cd983II1UxrIMujROPh4OXFDHWm/abLI=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">NHF: Standards and criteria for the care of patients with congenital bleeding disorders</a> (revised 2002)</p><p/><p class=\"headingAnchor\" id=\"H1820997536\"><span class=\"h1\">Europe</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.euhanet.org/docs/Euhanet-European_guidelines_for_the_certification_of_Haemophilia_Centres_2013.pdf&amp;token=hXgw0JqHo9syVb3P2q63ghlW1JRI4XCyRSl+JkMkP6fEX+BJujEBvX3zS7ofgXubqTBs/VmpJds1yeJQ1LUN6y2EcroPicVr6c+fEh2OwpAwFzHK4vK0LpmWnuf4oLgtGAbO7ZwYBPi1S9ewl+qYwQ==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">European Haemophilia Network (EUHANET): European guidelines for the certification of haemophilia centres</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2007.01625.x/epdf&amp;token=qTtMKq9nBOEYdHVACoWDdarX4n6aZnd6SOdTG8H+hH9AdeoRgUTpZoO3XimCXbypBVLfTz0CeCTKc1a3LKV60E5raR3yOyjcchSYc1OKAog=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">European Association for Haemophilia and Associated Disorders (EHAD): European principles of haemophilia care</a> (2008)</p><p/><p class=\"headingAnchor\" id=\"H448978195\"><span class=\"h1\">United Kingdom</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.15167&amp;token=9ETK4M5HIM6DovuDXt3qF/7+9JqQLdbzq2bfo8N/Qg4JgjHzvNhHL+Yx1MUpQzgYM8Ojg+e3b8uNwrTtV1GXrK8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">British Society of Haematology: Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products &ndash; Their handling and use in various patient groups in the absence of major bleeding</a> (2018)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/hae.13201/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKTSIcSSqHz1bieqe6BE8QgNE2HZxnmeCtiFfpQPq+uBVw==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">United Kingdom Haemophilia Centre Doctor's Organisation (UKHCDO): Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ukhcdo.org/wp-content/uploads/2017/01/ITI-protocol-2017.pdf&amp;token=+LDPjg1mwLO4cTgNgGMJVwvV8Ck76kdL+QeYAhoSpKIUPwvmLihXBJ7ZOgAJ8n+E79hAYDVugX52rqLae0hCRdpGhI/nts56NElNnqxJ2sw=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Protocol for first line immune tolerance induction for children with severe haemophilia A</a> (2017)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.nature.com/bdj/journal/v215/n10/pdf/sj.bdj.2013.1097.pdf&amp;token=uSByrg2RSatX8hwf9AkseEKUvH9geU+VQgdP7b5dNYnROeypTYYYdokmP/9wAKTBXKQ2/C4FUH1k7iSZqJyqwgGRbmsyG3sJHlFEFwo9NFo=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Guidance on the dental management of patients with haemophilia and congenital bleeding disorders</a> (2013, reviewed 2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ukhcdo.org/wp-content/uploads/2017/01/Enhanced-Half-Life-Guideline.Collins_et_al-2016-Haemophilia-2.pdf&amp;token=VDDq/j7U5vGN/INebPCfVsQAlPoBqMn6rnZYqDUXP/ldqlzAuJnItT3uPM7Hu4mKfeJ3usX2mKSw1S2niqzX+LFe7LzUn1iPsAhSuR4K5bLRf/HpfPmUQK+BFGswBVLAlai5pVC3JMFKprrO5gytRA==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Guidance on the use of enhanced half-life coagulation factor concentrates in routine clinical practice</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ukhcdo.org/wp-content/uploads/2015/12/Guidelines_on_genetics_services_for_haemophilia_v5-3_1_final.pdf&amp;token=lnJLjEZSOBQM5qqrLTCfa21QsgLEnXwHq4emz1fr/K4QpOYTnxZd599UKlUcB824Uv+d1eyTxQHWw/G53N1e4XcFvM/faPCF7oPaXY4fuUL62j+rU9Lec2k+VoJq5rFBsUH+nYZe4GtvWZJs5nDa9A==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Report on clinical genetic services for haemophilia</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.13058/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGeKEIubmaHkHRf+ZDkbB+gw==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Guideline for the diagnosis and management of the rare coagulation disorders</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.13064/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGCJeXZMItYLaUFQIakk6BwA==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Guideline for the diagnosis and management of von Willebrand disease</a> (2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08139.x/epdf&amp;token=DFE+ROwCdHgcGg1VlsZffGvehJYQ/QE04PxOFZVtqCYrjphECImUKUDMdL8SnzTbHPwlmXWJ7vjB0ltnBqi7uRubAjdVyvcgvkoNaZ/NT70=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A</a> (2010, reviewed 2014)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.12091/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGkCT1BsuZf+Z6ayR3/rS61g==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">BSH: Guideline for the diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia, 4th edition, 2012</a> (published 2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ukhcdo.org/wp-content/uploads/2015/12/EmergencyCareStandardsFinalVersionJune2009-For-Website.pdf&amp;token=RAzPsVmUgVxmNsJlWWMJW1V0DChecG7zrXdcwGzWCVThm/2EQkrIrHjGWwZZNwMW15lj81udjABFJTVr9b9nXxQtpL6CiN7bfo5VBt6pAkIw/xApT7oz1Ov8omiFEJj8+sGEnP/iwscjB8ADSG8htg==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Emergency and out of hours care of patients with bleeding disorders &ndash; Standards of care for assessment and treatment</a> (2009, reviewed 2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12139/full&amp;token=bdwu1RSbORl8JfbbsvcSbLYwO+k60zhwfpK+EVOF1VsNmEwazgPyLKSC5WWpkD42ksVN7V8Isv4FFBw6mITUR9/c7yM/nAta/J6jW9jY7zk=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Guidance on vaccination against hepatitis A and B viruses in patients with inherited coagulation factor deficiencies and von Willebrand disease, update</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.12463/epdf&amp;token=xvm30O72g3bVn6vV/GnkF9JPXsTaNt/t7iU9dZPqFKSBtjF4IFtG098sfOfLm7rGAwUXI5mXWsa3fHK+1zQIxg==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Guideline for the diagnosis and management of acquired coagulation inhibitors</a> (2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2008.01695.x/epdf&amp;token=c/fou9WsvMoeEBtnwzf/TqNCRT7745Vyj3pia9xKwdmP4ZJpBIoUK5C690eAZ7Twx7z1LO9E2OF2ikrEF3sSdb+F2Sxpj86ag71Sl/TOgBc=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders</a> (2008, reviewed 2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08545.x/epdf&amp;token=IgBfksGGkt3XYWtSwzH1kG8gQwuE+I8rt5pPHcXXVx8wjNbrq1SJfcsUOWOjuqcj4o9YV1qEzszLU7rsxA06gM1Wm0FRJH59zkxecKCYXPY=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">BSH: Guideline on the management of haemophilia in the fetus and neonate</a> (2011)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ukhcdo.org/wp-content/uploads/2015/12/Haemophilia-A-BPG-revision-Sept-2011-APPROVED.pdf&amp;token=C+vw0DixpJxPhVSHaHO30NwlQh2E/UFPpW7002yN6W12IsiUCDOFz3Sk387otloPPD5zMkuZnlnMffeAzp6Tefljrf5g7h84Wu9vbpuGTsx+SF4s2xQpn+zPVsNKUVqr3hn/WWnWjIlu0ACyXVjMSg==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Practice guidelines for the molecular diagnosis of haemophilia A</a> (2010)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ukhcdo.org/wp-content/uploads/2015/12/Haemophilia-B-BPG-revision-Sept-2011-APPROVED.pdf&amp;token=Qdr42r78jb14TS/aX3/p+CIYzjd7gGXvGj1iHBtBahPViTBRRkpEqy3j9H4qSOMG8h4Ub49rsbNGL2YOBzRtRHVGTLWaepJt5LcZxOfMlZgHID2SUzMzQSiIjA6zRSTd1AdcM+J9IiIx9d5Xdi0Ngg==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Practice guidelines for the molecular diagnosis of haemophilia B</a> (2010)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2008.01813.x/epdf&amp;token=GKa56oyB3h25nu8GvckoZ/kUhyHG1XKOMHJl3gTjeat/d0e11yMW2GpxKzuwOskJvUrCIothFIgIjMdt67LcCmeEQA+9cZhBG9VzsTjApyY=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Guideline on the molecular analysis of von Willebrand disease</a> (2008)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2006.01314.x/pdf&amp;token=ykvfvuw3G/G232VvNuHDkiae4UobqFQGyFbx/YuDDZ/AS1U24VIHaFQMx2vCgxWkmH1uCZBbTthy3dNTVmVSFlRMc5SdQyTwbn+10QJ/w4s=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: Review with guidelines for the obstetric and gynaecological management of women with inherited bleeding disorders</a> (2006)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2516.2005.01070.x/pdf&amp;token=qTtMKq9nBOEYdHVACoWDdarX4n6aZnd6SOdTG8H+hH9AdeoRgUTpZoO3XimCXbyp+Rck7DCf/cLh4wW/+UvOwUvLoE1PFBgKIWD0rQuptiU=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">UKHCDO: A framework for genetic service provision for haemophilia and other inherited bleeding disorders</a> (2005)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2141.2003.04256.x/epdf&amp;token=fJ4u3nktBC0v4jxxWAv7ZG3ppbLdQa9qx0QflpoHsZ1XydKQ5/HXoyln9CvpPHxeON2avQalAD5fKaIFMo9iX+dcznGVCj7jovY4gJM1LWY=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">BSH: Guidelines on fibrinogen assays</a> (2003)</p><p/><p class=\"headingAnchor\" id=\"H3637514402\"><span class=\"h1\">Australia</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.blood.gov.au/system/files/HaemophiliaGuidelines-interactive-updated-260317v2.pdf&amp;token=YZZj1cd/HVJ6SXxwvnRR1KbVTka+PWCNnZxzH+WfMG7u1RIYPZ3LpgL83MOUFd0a8pIsAsJL6STTRJcPSISrfYQrAUJlXkc6u+juuNckaozb9X8NSRDcmOj28rtQ0AOK&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">Australia Haemophilia Centre Directors' Organisation (AHCDO) and the National Blood Authority (NBA): Guidelines for the management of haemophilia in Australia</a> (2016)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ahcdo.org.au/documents/item/10&amp;token=PhLJGo2Jfx08+P2oUJD26n2EqBLeT52VS7jY3soVayP5bXH60TeTwO/6opVHCOrvtJqhhj+rqdjKG8Fd5a3g7Q==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">AHCDO: Guidelines for the management of factor VII deficiency</a> (2010)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ahcdo.org.au/documents/item/13&amp;token=PhLJGo2Jfx08+P2oUJD26n2EqBLeT52VS7jY3soVayNUWmPERw9+lfgzIH++EFOgvs4Hoc/rGAAVK+ou9EOVXw==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">AHCDO: Guidelines for the management of patients with haemophilia undergoing surgical procedures</a> (2010)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ahcdo.org.au/documents/item/15&amp;token=PhLJGo2Jfx08+P2oUJD26n2EqBLeT52VS7jY3soVayOOhFfpvW4nYlaAUQRk0DkXIxDYlR/CTsRPbnT6faotMA==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">AHCDO: Guidelines for the treatment of congenital disorders of fibrinogen</a> (2010)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ahcdo.org.au/documents/item/16&amp;token=PhLJGo2Jfx08+P2oUJD26n2EqBLeT52VS7jY3soVayPGhwgmrn6jUh3FIEM0/F1XVPNzhv8R9uQepgUe/OqIkQ==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">AHCDO: Guidelines for the treatment of inhibitors in haemophilia A and haemophilia B</a> (2010)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"https://www.mja.com.au/system/files/issues/191_08_191009/dun11341_fm.pdf&amp;token=OZfqKpidKQvoXO74qfpTmYVkBVtaL3BxLzF3U5PPkYRt9sASPaWxMBsKEa4G4cUyCNLQcXB/eGhlDVGCU0UMXkxOddKXwfEM7uPnY6WxlRE=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">AHCDO: A consensus statement on the management of pregnancy and delivery in women who are carriers of or have bleeding disorders</a> (2009)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ahcdo.org.au/documents/item/11&amp;token=PhLJGo2Jfx08+P2oUJD26n2EqBLeT52VS7jY3soVayM2tJtNU8wdMxVE1ziCT94S6rmHEpItijVfviP8PbmPfA==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">AHCDO: Guidelines for the management of HIV and hepatitis C infection in people with haemophilia</a> (2008)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ahcdo.org.au/documents/item/12&amp;token=PhLJGo2Jfx08+P2oUJD26n2EqBLeT52VS7jY3soVayMAp+uL0Hej5NjwHsVcDUBkp23I4fQi2FcmQvj3HuEVQg==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">AHCDO: Guidelines for management of pregnancy and delivery in women who are either carries or patients with bleeding disorders</a> (2007)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"http://www.ahcdo.org.au/documents/item/9&amp;token=PhLJGo2Jfx08+P2oUJD26n2EqBLeT52VS7jY3soVayMLd8doou0kAemg+x/G2OC2rwC1JCwUsNIWoeWxLU0oqw==&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">Australian Health Ministers' Advisory Council (AHMAC): Evidence-based clinical practice guidelines for the use of recombinant and plasma-derived FVIII and FIX products</a> (2006) </p><p/><p class=\"headingAnchor\" id=\"H3091721994\"><span class=\"h1\">Japan</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>[In Japanese] <a href=\"http://www.jsth.org/wordpress/wp-content/uploads/2015/04/ssc01_guidelines.pdf&amp;token=g6ofkElaZOaMQg1+cjFoLveqX80w77Q6beF4AT3+0gwqELGaS2tUgtwBgr7l48ZEIKxemHgUA9b29Leg7HV6btqA6OH6aZCLvRPUvPvTSjw=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">Japanese Society on Thrombosis and Hemostasis (JSTH): Clinical practice guidelines on acquired hemophilia A</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>[In Japanese] <a href=\"http://www.jsth.org/wordpress/wp-content/uploads/2015/04/自己免疫性出血病XIII13診断ガイド.pdf&amp;token=ymxOHvkf6xLe4R3zYrwNjgesLm0MpJLFccLKYvvNiMWZvr4nkZtDlqoiQ+8ClJY5UZdoWAWrvHp4jXoTlB7uYc5meFKnJBVXkHzCxRr48oUPOw8/ME7LGMgRpHrBbEWlvn++0gsmqgw99dvt1DECNTOO0cGPuQrG96Tm+leGhBs=&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">JSTH: Autoimmune hemorrhagic disease XIII diagnosis guide</a> (2015)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>[In Japanese] <a href=\"http://www.jsth.org/wordpress/wp-content/uploads/2015/04/04_HP用_インヒビター保有血友病患者に対する止血治療ガイドライン　2015年度補遺版.docx.pdf&amp;token=SMaCTqtxGcn+JK3sXNN0iOvEO97YC9o6BT515N7w+LcCBFMFU8WQWmrpnR9KmttRqlyLhmIhDQ82XfLpvNLzEBHRw+r/X1UfpudqTq0mFuSlGQvxY1AYgl7Sd1bOgyyK8B3lC5hXEiBkKwNUpp9ppzYWfMCTjYHRxtb0kuIhJ2FuaVtLyN1PSmNzlZrJBO0c/gY8BNhj/7eJuDjJ4BsTqeJJvCX4m0j0rWbk5fOWxCzKQciL/EyEf6im/FBdV+YD&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">JSTH: Guidelines for hemostasis treatment for hemophilia patients with inhibitors, supplement</a> (2015)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>[In Japanese] <a href=\"http://www.jsth.org/wordpress/wp-content/uploads/2015/04/03_HP用_インヒビター保有血友病患者に対する止血治療ガイドライン　2014年度補遺版.pdf&amp;token=SMaCTqtxGcn+JK3sXNN0iOvEO97YC9o6BT515N7w+LcCBFMFU8WQWmrpnR9KmttRHuaOuRBlmX5iLs9IjJCjEMJ2SgNuT8TKUpj7CuF08dGYfbhxgFa0YraBhD2NNC3WC0w1Rc2sTF6cz4oOdZY/0jtLCEyltPHNFnNd/vuwf3ECbqNco/7qcQQ+eyzrkhYdZikDP0a4cuh4mIxxElif043tS9PnWwrY0mW4HawXliWyVUb8cyIh1Ecor8tjdJUP&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">JSTH: Guidelines for hemostasis treatment for hemophilia patients with inhibitors, supplement</a> (2014)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>[In Japanese] <a href=\"http://www.jsth.org/wordpress/wp-content/uploads/2015/04/03_inhibitor_H1_A.pdf&amp;token=UbPxs578ryg/83o3VR5/b1+LIvSOn0j3/NlRPwms1PfSqSDf1u5NsZRjOXpQRq4Lq+vw8HMS4W0yRAKiSQX0aZghEgnSfAMUyt5bd4tKFek3Wn8vgyUm7vbR5UOuIMU7&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">JSTH: Guidelines for hemostasis treatment for congenital hemophilia patients with inhibitors</a> (revised 2013)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>[In Japanese] <a href=\"http://www.jsth.org/wordpress/wp-content/uploads/2015/04/02_HP用_インヒビターのない血友病患者に対する止血治療ガイドライン　2015年度補遺版.pdf&amp;token=SMaCTqtxGcn+JK3sXNN0iOvEO97YC9o6BT515N7w+LcCBFMFU8WQWmrpnR9KmttR8wyhUJqs1ob4rMq3RlXWHcJ2SgNuT8TKUpj7CuF08dE0HqSuUrGJuWRzdvnX+gPPvJt+oh4le0YiEW8YU4wuUI8tBi7IieLC8l+VF1yNxV0rUr3WpQX4ZR6SPnye3aXyd9jh23VAVD1DpTlNKOTIaI0fHABdZ3ta2rKU3yHNiVjd/I35QpdwO/bqVM/wC/SI&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">JSTH: Guidelines for hemostasis treatment for hemophilia patients without inhibitors, supplement</a> (2015)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>[In Japanese] <a href=\"http://www.jsth.org/wordpress/wp-content/uploads/2015/04/01_HP用_インヒビターのない血友病患者に対する止血治療ガイドライン　2014年度補遺版.pdf&amp;token=SMaCTqtxGcn+JK3sXNN0iOvEO97YC9o6BT515N7w+LcCBFMFU8WQWmrpnR9KmttRAPm0iML6taLdWTCdk8Pje8J2SgNuT8TKUpj7CuF08dE0HqSuUrGJuWRzdvnX+gPPvJt+oh4le0YiEW8YU4wuUI8tBi7IieLC8l+VF1yNxV0rUr3WpQX4ZR6SPnye3aXyCeHigx5Y3Grv8CM8bg/5RqWOoXPPhmDmdGJXij198sWIj883OsNqrxtF/CkjC3zC&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">JSTH: Guidelines for hemostasis treatment for hemophilia patients without inhibitors, supplement</a> (revised 2014)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>[In Japanese] <a href=\"http://www.jsth.org/wordpress/wp-content/uploads/2015/04/03_inhibitor_H1_B.pdf&amp;token=UbPxs578ryg/83o3VR5/bx4K8OG1xv2AO8QgNtvamZ/SqSDf1u5NsZRjOXpQRq4Lq+vw8HMS4W0yRAKiSQX0aaJetKJ4JS0859vXYy9JZ1LmPtBdKRxfUdBVc6PR2QGM&amp;TOPIC_ID=112393\" target=\"_blank\" class=\"external\">JSTH: Guidelines for hemostasis treatment for hemophilia patients without inhibitors</a> (revised 2013)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 112393 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H3393918008\" id=\"outline-link-H3393918008\">Introduction</a></li><li><a href=\"#H1985356292\" id=\"outline-link-H1985356292\">International</a></li><li><a href=\"#H947502612\" id=\"outline-link-H947502612\">Canada</a></li><li><a href=\"#H3915409515\" id=\"outline-link-H3915409515\">United States</a></li><li><a href=\"#H1820997536\" id=\"outline-link-H1820997536\">Europe</a></li><li><a href=\"#H448978195\" id=\"outline-link-H448978195\">United Kingdom</a></li><li><a href=\"#H3637514402\" id=\"outline-link-H3637514402\">Australia</a></li><li><a href=\"#H3091721994\" id=\"outline-link-H3091721994\">Japan</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-immune-thrombocytopenia-itp-and-other-platelet-disorders\" class=\"medical medical_society_guidelines\">Society guideline links: Immune thrombocytopenia (ITP) and other platelet disorders</a></li></ul></div></div>","javascript":null}